• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

定量分析人肝组织和原代肝细胞中的有机阴离子转运蛋白 OAT2 和 OAT7。

Quantification of Hepatic Organic Anion Transport Proteins OAT2 and OAT7 in Human Liver Tissue and Primary Hepatocytes.

机构信息

Pharmacokinetics, Dynamics and Metabolism, Medicine Design , Pfizer Worldwide R&D , Groton , Connecticut 06340 , United States.

出版信息

Mol Pharm. 2018 Aug 6;15(8):3227-3235. doi: 10.1021/acs.molpharmaceut.8b00320. Epub 2018 Jun 25.

DOI:10.1021/acs.molpharmaceut.8b00320
PMID:29906129
Abstract

Organic anion transporter (OAT) 2 and OAT7 were recently shown to be involved in the hepatic uptake of drugs; however, there is limited understanding of the population variability in the expression of these transporters in liver. There is also a need to derive relative expression-based scaling factors (REFs) that can be used to bridge in vitro functional data to the in vivo drug disposition. To this end, we quantified OAT2 and OAT7 surrogate peptide abundance in a large number of human liver tissue samples ( n = 52), as well as several single-donor cryopreserved human hepatocyte lots ( n = 30) by a novel, validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. The average surrogate peptide expression of OAT2 and OAT7 in the liver samples was 1.52 ± 0.57 and 4.63 ± 1.58 fmol/μg membrane protein, respectively. While we noted statistically significant differences ( p < 0.05) in hepatocyte and liver tissue abundances for both OAT2 and OAT7, the differences were relatively small (1.8- and 1.5-fold difference in median values, respectively). Large interindividual variability was noted in the hepatic expression of OAT2 (16-fold in liver tissue and 23-fold in hepatocytes). OAT7, on the other hand, showed less interindividual variability (4-fold) in the livers, but high variability for the hepatocyte lots (27-fold). A significant positive correlation in OAT2 and OAT7 expression was observed, but expression levels were neither associated with age nor sex. In conclusion, our data suggest marked interindividual variability in the hepatic expression of OAT2/7, which may contribute to the pharmacokinetic variability of their substrates. Because both transporters were less abundant in hepatocytes than livers, a REF-based approach is recommended when scaling in vitro hepatocyte transport data to predict hepatic drug clearance and liver exposure of OAT2/7 substrates.

摘要

有机阴离子转运体 (OAT) 2 和 OAT7 最近被证明参与了药物在肝脏中的摄取;然而,对于这些转运体在肝脏中的表达的人群变异性,人们的了解有限。还需要推导出相对表达基础缩放因子 (REF),以便将体外功能数据与体内药物处置联系起来。为此,我们通过一种新的经过验证的液相色谱串联质谱 (LC-MS/MS) 方法,定量了大量人肝组织样本 (n=52) 和多个单供体冷冻保存的人肝细胞批次 (n=30) 中的 OAT2 和 OAT7 替代肽丰度。肝组织样本中 OAT2 和 OAT7 的替代肽平均表达分别为 1.52±0.57 和 4.63±1.58 fmol/μg 膜蛋白。虽然我们注意到 OAT2 和 OAT7 在肝细胞和肝组织中的丰度存在统计学上的显著差异 (p<0.05),但差异相对较小 (中位数分别相差 1.8 倍和 1.5 倍)。OAT2 在肝脏中的表达存在很大的个体间变异性 (肝组织中为 16 倍,肝细胞中为 23 倍)。另一方面,OAT7 在肝脏中的个体间变异性较小 (4 倍),但肝细胞批次的变异性较大 (27 倍)。观察到 OAT2 和 OAT7 表达之间存在显著的正相关,但表达水平与年龄或性别无关。总之,我们的数据表明 OAT2/7 在肝脏中的表达存在明显的个体间变异性,这可能导致其底物的药代动力学变异性。由于这两种转运体在肝细胞中的丰度均低于肝脏,因此建议在将体外肝细胞转运数据缩放以预测 OAT2/7 底物的肝清除率和肝脏暴露时,采用基于 REF 的方法。

相似文献

1
Quantification of Hepatic Organic Anion Transport Proteins OAT2 and OAT7 in Human Liver Tissue and Primary Hepatocytes.定量分析人肝组织和原代肝细胞中的有机阴离子转运蛋白 OAT2 和 OAT7。
Mol Pharm. 2018 Aug 6;15(8):3227-3235. doi: 10.1021/acs.molpharmaceut.8b00320. Epub 2018 Jun 25.
2
In vitro studies with two human organic anion transporters: OAT2 and OAT7.对两种人类有机阴离子转运体OAT2和OAT7的体外研究。
Xenobiotica. 2018 Oct;48(10):1037-1049. doi: 10.1080/00498254.2017.1384595. Epub 2017 Oct 13.
3
Role of Hepatic Organic Anion Transporter 2 in the Pharmacokinetics of R- and S-Warfarin: In Vitro Studies and Mechanistic Evaluation.肝脏有机阴离子转运蛋白 2 在 R-和 S-华法林药代动力学中的作用:体外研究和机制评估。
Mol Pharm. 2018 Mar 5;15(3):1284-1295. doi: 10.1021/acs.molpharmaceut.7b01108. Epub 2018 Feb 20.
4
Organic Anion Transporter 2 Mediates Hepatic Uptake of Tolbutamide, a CYP2C9 Probe Drug.有机阴离子转运体 2 介导甲苯磺丁脲(CYP2C9 探针药物)的肝脏摄取。
J Pharmacol Exp Ther. 2018 Mar;364(3):390-398. doi: 10.1124/jpet.117.245951. Epub 2018 Jan 11.
5
The human organic anion transporter genes OAT5 and OAT7 are transactivated by hepatocyte nuclear factor-1α (HNF-1α).人有机阴离子转运体基因 OAT5 和 OAT7 可被肝细胞核因子-1α(HNF-1α)转激活。
Mol Pharmacol. 2010 Dec;78(6):1079-87. doi: 10.1124/mol.110.065201. Epub 2010 Sep 9.
6
Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs.有机阴离子转运体 2 介导的肝摄取有助于清除高通透性-低分子量酸性和两性离子药物:25 种药物的评估。
J Pharmacol Exp Ther. 2018 Nov;367(2):322-334. doi: 10.1124/jpet.118.252049. Epub 2018 Aug 22.
7
Comparison of Proteomic Quantification Approaches for Hepatic Drug Transporters: Multiplexed Global Quantitation Correlates with Targeted Proteomic Quantitation.肝药物转运体的蛋白质组定量方法比较:多重全局定量与靶向蛋白质组定量相关。
Drug Metab Dispos. 2018 May;46(5):692-696. doi: 10.1124/dmd.117.079285. Epub 2018 Feb 8.
8
Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data.基于转运蛋白表达和活性数据预测有机阴离子转运多肽1B1和1B3介导的他汀类药物肝摄取
Drug Metab Dispos. 2014 Sep;42(9):1514-21. doi: 10.1124/dmd.114.058412. Epub 2014 Jul 2.
9
Meta-analysis of expression of hepatic organic anion-transporting polypeptide (OATP) transporters in cellular systems relative to human liver tissue.细胞系统中肝脏有机阴离子转运多肽(OATP)转运体表达相对于人类肝脏组织的荟萃分析。
Drug Metab Dispos. 2015 Apr;43(4):424-32. doi: 10.1124/dmd.114.062034. Epub 2015 Jan 6.
10
Variability in hepatic expression of organic anion transporter 7/SLC22A9, a novel pravastatin uptake transporter: impact of genetic and regulatory factors.新型普伐他汀摄取转运体有机阴离子转运体7/SLC22A9肝脏表达的变异性:遗传和调节因素的影响
Pharmacogenomics J. 2016 Aug;16(4):341-51. doi: 10.1038/tpj.2015.55. Epub 2015 Aug 4.

引用本文的文献

1
From Discovery to Translation: Endogenous Substrates of OAT1 and OAT3 as Clinical Biomarkers for Renal Secretory Function.从发现到转化:OAT1和OAT3的内源性底物作为肾脏分泌功能的临床生物标志物
Clin Pharmacol Ther. 2025 Sep;118(3):693-704. doi: 10.1002/cpt.3719. Epub 2025 May 22.
2
..
Drug Metab Dispos. 2021 Dec 17;50(9):1193-210. doi: 10.1124/dmd.121.000702.
3
The Person's Care Requires a Sex and Gender Approach.对该患者的护理需要采用性别视角。
J Clin Med. 2021 Oct 18;10(20):4770. doi: 10.3390/jcm10204770.
4
Function of Uric Acid Transporters and Their Inhibitors in Hyperuricaemia.尿酸转运体及其抑制剂在高尿酸血症中的作用
Front Pharmacol. 2021 Jul 14;12:667753. doi: 10.3389/fphar.2021.667753. eCollection 2021.
5
Recent developments in and models for improved translation of preclinical pharmacokinetics and pharmacodynamics data.临床前药代动力学和药效学数据转化的 和 模型的最新进展。
Drug Metab Rev. 2021 May;53(2):207-233. doi: 10.1080/03602532.2021.1922435. Epub 2021 May 25.
6
Quantification of P-Glycoprotein in the Gastrointestinal Tract of Humans and Rodents: Methodology, Gut Region, Sex, and Species Matter.人及啮齿类动物胃肠道 P 糖蛋白的定量:方法学、肠道区域、性别和物种很重要。
Mol Pharm. 2021 May 3;18(5):1895-1904. doi: 10.1021/acs.molpharmaceut.0c00574. Epub 2021 Apr 22.
7
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)-Based Proteomics of Drug-Metabolizing Enzymes and Transporters.基于液质联用技术的药物代谢酶和转运体的蛋白质组学研究。
Molecules. 2020 Jun 11;25(11):2718. doi: 10.3390/molecules25112718.
8
Are Standard Doses of Renally-Excreted Antiretrovirals in Older Patients Appropriate: A PBPK Study Comparing Exposures in the Elderly Population With Those in Renal Impairment.标准剂量的经肾排泄抗逆转录病毒药物是否适用于老年患者:一项比较老年人群与肾功能损害人群暴露情况的 PBPK 研究。
Drugs R D. 2019 Dec;19(4):339-350. doi: 10.1007/s40268-019-00285-0.